Background: Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …

In a retrospective study, we compared the incidence and risk of mortality associated with
CMV disease in adult allogeneic BMT and PBSC recipients who received ganciclovir …

Objective: To evaluate the efficacy and safety of ganciclovir for prevention of
cytomegalovirus (CMV) infection and disease. Design: A randomized, placebo-controlled …

Background. Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality
after allogeneic bone marrow transplantation. We conducted a controlled trial of ganciclovir …

Ganciclovir is a nucleoside analogue which is used to treat and prevent cytomegalovirus
(CMV) infection. Most recent clinical studies of ganciclovir in transplant recipients have …

The purposes of this review are to examine the epidemiology of disease due to
cytomegalovirus (CMV) in recipients of autologous and allogeneic marrow transplants and …

We prospectively monitored 61 allogeneic BMT patients for evidence of CMV infection and
disease starting 7 days prior to transplant until day 110 after transplant. Patients receiving …

Cytomegalovirus (CMV) infection is one of the most common causes of morbidity and
mortality after allogeneic marrow transplantation. We studied 14 consecutive CMV …

Ganciclovir was given prophylactically to 25 patients receiving allogeneic bone marrow
transplants for haematological malignancy. Patients who were seropositive for …

Cytomegalovirus (CMV) disease remains a major cause of morbidity following allogeneic
stem cell transplantation (SCT). In a prospective randomized trial, we tested prophylactic …